Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Retained Earnings (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Retained Earnings readings, the most recent being -$281.2 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 0.84% to -$281.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$281.2 million, a 0.84% decrease, with the full-year FY2025 number at -$281.2 million, down 0.84% from a year prior.
  • Retained Earnings hit -$281.2 million in Q4 2025 for Arcadia Biosciences, roughly flat from -$279.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $161000.0 in Q1 2024 to a low of -$281.2 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$266.8 million (2023), compared with a mean of -$234.1 million.
  • Biggest five-year swings in Retained Earnings: plummeted 2089066.67% in 2022 and later surged 100.06% in 2024.
  • Arcadia Biosciences' Retained Earnings stood at -$226.5 million in 2021, then fell by 13.85% to -$257.9 million in 2022, then decreased by 5.42% to -$271.8 million in 2023, then decreased by 2.59% to -$278.9 million in 2024, then decreased by 0.84% to -$281.2 million in 2025.
  • The last three reported values for Retained Earnings were -$281.2 million (Q4 2025), -$279.9 million (Q3 2025), and -$280.7 million (Q2 2025) per Business Quant data.